Colchicine Use for Primary Prevention of Coronary Artery Disease
Status:
Not yet recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Colchicine has been widely used as an anti-gout medicine in the past decades. Some recent
clinical trials have proved that low-dose colchicine can be used as a secondary prevention
drug for coronary artery disease because of its anti-inflammatory mechanism. However, the
effect on primary prevention has not been observed sufficiently. The objective of this study
is to determine whether colchicine reduces the incidence of CAD in patients and its safety
for long-term use.